Chapter 12 Topical sensitization-oncologic indications-actinic keratoses

Comprehensive Series in Photosciences

Volumn 2, Issue C, 2001, Pages 199-216

  Sidoroff, Alexis ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957085691     PISSN: 1568461X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1568-461X(01)80116-2     Document Type: Article

References (95)

1. Marks R., Rennie G., and Selwood T.S. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1 8589 (1988) 795-797
2. Graham J.H. Precancerous lesions of the skin. Prim. Care 2 (1976) 699-716
3. Pt 2. Glogau R.G. The risk of progression to invasive disease. J. Am. Acad. Dermatol. 42 1 (2000) 23-24
4. Ng P., and Ackermann A.B. The major types of squamous-cell carcinoma. Dermatopathol: Pract. and Conc. 5 3 (1999) 250-252
5. Ackermann A.B. Respect at last for solar keratosis (Editorial). Dermatopathol: Pract. and Conc. 3 2 (1997) 101-103
6. Ziegler A., Jonason A.S., Leffell D.J., Simon J.A., Sharma H.W., Kimmelman J., et al. Sunburn and p53 in the onset of skin cancer [see comments]. Nature 372 6508 (1994) 773-776
7. Frost C., Williams G., and Green A. High incidence and regression rates of solar keratoses in a queensland community. J. Invest. Dermatol. 115 2 (2000) 273-277
8. Vogelstein B., and Kinzler K.W. The multistep nature of cancer. Trends Genet. 9 4 (1993) 138-141
9. Ziegler A., Leffell D.J., Kunala S., Sharma H.W., Gailani M., Simon J.A., et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc. Natl. Acad. Sci. USA 90 9 (1993) 4216-4220
10. Brash D.E., Ziegler A., Jonason A.S., Simon J.A., Kunala S., and Leffell D.J. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J. Investig. Dermatol Symp. Proc. 1 2 (1996) 136-142
11. Vitasa B.C., Taylor H.R., Strickland P.T., Rosenthal F.S., West S., Abbey H., et al. Association of nonmelanoma skin cancer and actinic keratosis with cumulative solar ultraviolet exposure in Maryland watermen. Cancer 65 12 (1990) 2811-2817
12. Marks R. Solar keratoses. Br. J. Dermatol. 35 Suppl 122 (1990) 49-54
13. Green A., Beardmore G., Hart V., Leslie D., Marks R., and Staines D. Skin cancer in a Queensland population. J. Am. Acad. Dermatol. 19 6 (1988) 1045-1052
14. Marks R., Jolley D., Dorevitch A.P., and Selwood T.S. The incidence of non-melanocytic skin cancers in an Australian population: results of a five-year prospective study. Med. J. Aust. 150 9 (1989) 475-478
15. Marks R., Staples M., and Giles G.G. Trends in non-melanocytic skin cancer treated in Australia: the second national survey. Int. J. Cancer 53 4 (1993) 585-590
16. (Suppl). Marks R. An overview of skin cancers. Incidence and causation. Cancer 75 2 (1995) 607-612
17. Frost C.A., and Green A.C. Epidemiology of solar keratoses. Br. J. Dermatol. 131 4 (1994) 455-464
18. Harvey I., Frankel S., Marks R., and Shalom D. Nolan-Farrell M. Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study. Br. J. Cancer 74 8 (1996) 1302-1307
19. Harvey I., Frankel S., Marks R., Shalom D., and Nolan-Farrell M. Non-melanoma skin cancer and solar keratoses II analytical results of the South Wales Skin Cancer Study. Br. J. Cancer 74 8 (1996) 1308-1312
20. Johnson M.T., and Roberts J. Skin conditions and related need for medical care among persons 1-74 years United States, 1971-1974. Vital Health Stat 11 212 (1978) i-v
21. Johnson M.T., and Roberts J. Skin conditions and related need for medical care among persons 1-74 years. United States, 1971-1974. Vital Health Stat. 11 212 (1978) 1-72
22. Pt 2. Moy R.L. Clinical presentation of actinic keratoses and squamous cell carcinoma. J. Am. Acad. Dermatol. 42 1 (2000) 8-10
23. Dinehart S.M., Nelson-Adesokan P., Cockerell C., Russell S., and Brown R. Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis. Cancer 79 5 (1997) 920-923
24. Drake L.A., Ceilley R.I., Cornelison R.L., Dobes W.L., Dorner W., Goltz R.W., et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J. Am. Acad. 32 1 (1995) 95-98
25. Feldman S.R., Fleischer Jr. A.B., Williford P.M., and Jorizzo J.L. Destructive procedures are the standard of care for treatment of actinic keratoses. J. Am. Acad. Dermatol. 40 1 (1999) 43-47
26. Holt P.J. Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery. Br. J. Dermatol. 119 2 (1988) 231-240
27. Lubritz R.R., and Smolewski S.A. Cryosurgery cure rate of actinic keratoses. J. Am. Acad. Dermatol. 7 5 (1982) 631-632
28. Chiarello S.E. Full-face cryo- (liquid nitrogen) peel. J. Dermatol. Surg. Oncol. 18 4 (1992) 329-332
29. Chiarello S.E. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol. Surg. 26 8 (2000) 728-732
30. Coleman III W.P., Yarborough J.M., and Mandy S.H. Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol. Surg. 22 1 (1996) 17-21
31. Trimas S.J., Ellis D.A., and Metz R.D. The carbon dioxide laser. An alternative for the treatment of actinically damaged skin [see comments]. Dermatol. Surg. 23 10 (1997) 885-889
32. 2 lasers for prophylaxis of keratoses and cancers [see comments]. Dermatol. Surg. 25 9 (1999) 729-732
33. Dmovsek-Olup B., and Vedlin B. Use of Er:YAG laser for benign skin disorders. Lasers Surg. Med. 21 1 (1997) 13-19
34. Jiang S.B., Levine V.J., Nehal K.S., Baldassano M., Kamino H., and Ashinoff R.A. Er:YAG laser for the treatment of actinic keratoses. Dermatol. Surg. 26 5 (2000) 437-440
35. Eaglstein W.H., Weinstein G.D., and Frost P. Fluorouracil: mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch. Dermatol. 101 2 (1970) 132-139
36. Dillaha C.J., Jansen G.T., Honeycutt W.M., and Bradford A.C. Selective cytotoxic effect of topical 5-fluorouracil. Arch. Dermatol. 119 9 (1983) 774-783
37. Unis M.E. Short-term intensive 5-fluorouracil treatment of actinic keratoses [see comments]. Dermatol. Surg. 21 2 (1995) 162-163
38. Pearlman D.L. Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J. Am. Acad. Dermatol. 25 4 (1991) 665-667
39. Epstein E. Does intermittent "pulse" topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation?. J. Am. Acad. Dermatol. 38 1 (1998) 77-80
40. Pt 1. Olsen E.A., Abernethy M.L., Kulp-Shorten C., Callen J.P., Glazer S.D., Huntley A., et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck [see comments]. J. Am. Acad. Dermatol. 24 5 (1991) 738-743
41. Pt 1. Epstein E. Warning! Masoprocol is a potent sensitizer [letter; comment]. J. Am. Acad. Dermatol. 31 2 (1994) 295-297
42. [published erratum appears in Mayo Clin. Proc., 63(11, Nov. 1988), 1122]. Brodland D.G., and Roenigk R.K. Trichloroacetic acid chemexfoliation (chemical peel) for extensive premalignant actinic damage of the face and scalp. Mayo Clin. Proc. 63 9 (1988) 887-896
43. Stone P.A. The use of modified phenol for chemical face peeling. Clin. Plast. Surg. 25 1 (1998) 21-44
44. Tse Y., Ostad A., Lee H.S., Levine V.J., Koenig K., Kamino H., et al. A clinical and histologic evaluation of two medium-depth peels. Glycolic acid versus Jessner's trichloroacetic acid. Dermatol. Surg. 22 9 (1996) 781-786
45. Lawrence N., Cox S.E., Cockerell C.J., Freeman R.G., and Cruz Jr. P.D. A comparison fluororacil in the treatment of widespread facial actinic keratoses. Arch. Dermatol. 131 2 (1995) 176-181
46. Edwards L., Levine N., Weidner M., Piepkorn M., and Smiles K. Effect of intralesional alpha 2-interferon on actinic keratoses. Arch. Dermatol. 122 7 (1986) 779-782
47. Shuttleworth D., and Marks R. A comparison of the effects of intralesional interferon a-2b and topical 5% fluorouracil cream in the treatment of solar keratoses and Bowen's disease. J. Dermatol. Treat. 1 (1989) 91-93
48. Edwards L., Levine N., and Smiles K.A. The effect of topical interferon alpha 2b on actinic keratoses. J. Dermatol. Surg. Oncol. 16 5 (1990) 446-449
49. Alirezai M., Dupuy P., Amblard P., Kalis B., Souteyrand P., Frappaz A., et al. Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses. J. Am. Acad. Dermatol. 30 3 (1994) 447-451
50. Bollag W., and Ott F. Retinoic acid: topical treatment of senile or actinic keratoses and basal cell carcinomas. Agents Actions 1 4 (1970) 172-175
51. Rivers J.K., and McLean D.I. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch. Dermatol. 133 10 (1997) 1239-1242
52. Burgess G.H., Block A., Stoll H., Milgrom H., Helm F., and Klein E. Effect of topical tubercidin on basal cell carcinomas and actinic keratoses. Cancer 34 2 (1974) 250-253
53. Cham B.E., Daunter B., and Evans R.A. Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides. Cancer Lett. 59 3 (1991) 183-192
54. Griffin T.D., and Van Scott E.J. Use of pyruvic acid in the treatment of actinic keratoses: a clinical and histopathologic study. Cutis 47 5 (1991) 325-329
55. Marrero G.M., and Katz B.E. The new fluor-hydroxy pulse peel. A combination of 5-fluorouracil and glycolic acid. Dermatol. Surg. 24 9 (1998) 973-978
56. Bercovitch L. Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-fluorouracil: a double-blind controlled study. Br. J. Dermatol. 116 4 (1987) 549-552
57. Humphreys T.R., Werth V., Dzubow L., and Kligman A. Treatment of photodamaged skin with trichloroacetic acid and topical tretinoin. J. Am. Acad. Dermatol. 34 4 (1996) 638-644
58. Majewski S., Skopinska M., Bollag W., and Jablonska S. Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions [letter]. Lancet 344 8935 (1994) 1510-1511
59. Szeimies R.M., Calzavara-Pinton P., Karrer S., Ortel B., and Landthaler M. Topical photodynamic therapy in dermatology. J. Photochem. Photobiol. B 36 2 (1996) 213-219
60. Fritsch C., Goerz G., and Ruzicka T. Photodynamic therapy in dermatology. Arch. Dermatol. 134 2 (1998) 207-214
61. Harth Y., Hirshowitz B., and Kaplan B. Modified topical photodynamic therapy of superficial skin tumors, utilizing aminolevulinic acid, penetration enhancers, red light, and hyperthermia. Dermatol. Surg. 24 7 (1998) 723-726
62. Rebeiz N., Rebeiz C.C., Arkins S., Kelley K.W., and Rebeiz C.A. Photodestruction of tumor cells by induction of endogenous accumulation of protoporphyrin IX: enhancement by 1,10-phenanthroline. Photochem. Photobiol. 55 3 (1992) 431-435
63. Rebeiz N., Arkins S., Rebeiz C.A., Simon J., Zachary J.F., and Kelley K.W. Induction of tumor necrosis by delta-aminolevulinic acid and 1,10-phenanthroline photodynamic therapy. Cancer Res. 56 2 (1996) 339-344
64. Ortel B., Tanew A., and Honigsmann H. Lethal photosensitization by endogenous porphyrins of PAM cells-modification by desferrioxamine. J. Photochem. Photobiol. B 17 3 (1993) 273-278
65. Fijan S., Honigsmann H., and Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br. J. Dermatol. 133 2 (1995) 282-288
66. Abels C., Szeimies R.M., Steinbach P., Richert C., and Goetz A.E. Targeting of the tumor microcirculation by photodynamic therapy with a synthetic porphycene. J. Photochem. Photobiol. B 40 3 (1997) 305-312
67. Aramendia P.F., Redmond R.W., Nonell S., Schuster W., Braslavsky S.E., Schaffner K., et al. The photophysical properties of porphycenes: potential photodynamic therapy agents. Photochem. Photobiol. 44 5 (1986) 555-559
68. Guardiano M., Biolo R., Jori G., and Schaffner K. Tetra-n-propylporphycene as a tumour localizer: pharmacokinetic and phototherapeutic studies in mice. Cancer Lett. 44 1 (1989) 1-6
69. Karrer S., Abels C., Szeimies R.M., Baumler W., Dellian M., Hohenleutner U., et al. Topical application of a first porphycene dye for photodynamic therapy-penetration studies in human perilesional skin and basal cell carcinoma. Arch. Dermatol. Res. 289 3 (1997) 132-137
70. Richert C., Wessels J.M., Muller M., Kisters M., Benninghaus T., and Goetz A.E. Photodynamic antitumor agents: beta-methoxyethyl groups give access to functionalized porphycenes and enhance cellular uptake and activity. J. Med. Chem. 37 17 (1994) 2797-2807
71. Szeimies R.M., Karrer S., Abels C., Steinbach P., Fickweiler S., Messmann H., et al. 9-Acetoxy-2,7,12,17-tetrakis-(beta-methoxyethyl)-porphycene (ATMPn), a novel photosensitizer for photodynamic therapy: uptake kinetics and intracellular localization. J. Photochem. Photobiol. B 34 1 (1996) 67-72
72. Sacchini V., Melloni E., Marchesini R., Fabrizio T., Cascinelli N., Santoro O., et al. Topical administration of tetrasodium-meso-tetraphenylporphinesulfonate (TPPS) and red light irradiation for the treatment of superficial neoplastic lesions. Tumori 73 1 (1987) 19-23
73. Hohenleutner U., Szeimies R.M., and Landthaler M. Photodynamische Therapie zur Behandlung oberflächlicher Basaliome. In: Braun-Falco O., Plewig G., and Meurer M. (Eds). Fortschritte der praktischen Dermatologie und Venerologie (1993), Springer, Berlin, Heidelberg, New York 472-474
74. Winkelman J.W., and Collins G.H. Neurotoxicity of tetraphenylporphinesulfonate TPPS4 and its relation to photodynamic therapy. Photochem. Photobiol. 46 5 (1987) 801-807
75. Forbes I.J., Cowled P.A., Leong A.S., Ward A.D., Black R.B., Blake A.J., et al. Phototherapy of human tumours using haematoporphyrin derivative. Med. J. Aust. 2 9 (1980) 489-493
76. Kennedy J.C., Pottier R.H., and Pross D.C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J. Photochem. Photobiol. B 6 1-2 (1990) 143-148
77. Szeimies R.M., Hein R., Baumler W., Heine A., and Landthaler M. A possible new incoherent lamp for photodynamic treatment of superficial skin lesions. Acta Derm. Venereol. 74 2 (1994) 117-119
78. Szeimies R.M., Abels C., Fritsch C., Karrer S., Steinbach P., Baumler W., et al. Wavelength dependency of photodynamic effects after sensitization with 5-aminolevulinic acid in vitro and in vivo. J. Invest. Dermatol. 105 5 (1995) 672-677
79. Cairnduff F., Stringer M.R., Hudson E.J., Ash D.V., and Brown S.B. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br. J. Cancer 69 3 (1994) 605-608
80. Stern R.S., and Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer 73 11 (1994) 2759-2764
81. Stern R., Zierler S., and Parrish J.A. Psoriasis and the risk of cancer. J. Invest. Dermatol. 78 2 (1982) 147-149
82. Runger T.M. DNA damage to the skin caused by ultraviolet irradiation. Development, significance, modification. Med. Klin. (Suppl) 90 1 (1995) 22-26
83. Wolf P., Fink-Puches R., Reimann-Weber A., and Kerl H. Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. Dermatology 194 1 (1997) 53-54
84. Fuchs J., Weber S., and Kaufmann R. Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: implications for clinical photodynamic therapy. Free Radic. Biol. Med. 28 4 (2000) 537-548
85. von Tappeiner H., and Jesionek A. Therapeutische Versuche mit fluorescierenden Stoffen. Münch. Med. Wochenschr. 47 (1903) 2042-2044
86. [published erratum appears in J. Am. Acad. Dermatol., Jul. 29(1), 41]. Wolf P., Rieger E., and Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas?. J. Am. Acad. Dermatol. 28 1 (1993) 17-21
87. Hurlimann A.F., Panizzon R.G., and Burg G. Topical photodynamic treatment of tumors and dermatoses. Dermatology 3 (1994) 327
88. Calzavara-Pinton P.G. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J. Photochem. Photobiol. B 29 1 (1995) 53-57
89. Szeimies R.M., Karrer S., Sauerwald A., and Landthaler M. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology 192 3 (1996) 246-251
90. Pt 1. Kurwa H.A., Yong-Gee S.A., Seed P.T., Markey A.C., and Barlow R.J. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J. Am. Acad. Dermatol. 41 3 (1999) 414-418
91. Jeffes E.W., McCullough J.L., Weinstein G.D., Fergin P.E., Nelson J.S., Shull T.F., et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch. Dermatol. 133 6 (1997) 727-732
92. Ormrod D., and Jarvis B. Topical Aminolevulinic Acid HCL Photodynamic Therapy. Am. J. Clin. Dermatol. 1 2 (2000) 133-139
93. Karrer S., Baumler W., Abels C., Hohenleutner U., Landthaler M., and Szeimies R.M. Long-pulse dye laser for photodynamic therapy: investigations in vitro and in vivo. Lasers Surg. Med. 25 1 (1999) 51-59
94. Szeimies R.M., Karrer S., Heine A., Hohenleutner U., and Landthaler M. Topical photodynamic therapy with 5-aminolevulinic acid in the treatment of arsenic-induced skin tumors. Eur. J. Dermatol. 5 (1995) 208-211
95. Fink-Puches R., Soyer H.P., Hofer A., Kerl H., and Wolf P. Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy. Arch. Dermatol. 134 7 (1998) 821-826